研究单位：[1]Xuanwu Hospital,Capital Medical University Beijing,Beijing,China,100054[2]Beijing Neoantigen Biotechnology Company
研究目的：
A single-arm, single-center, open-labeled study will be conducted with an aim to investigate the feasibility, safety, and efficacy of the personalized vaccine for patients with recurrent malignant glioma.
